Anthrax spores make an essential contribution to vaccine efficacy
- PMID: 11796596
- PMCID: PMC127709
- DOI: 10.1128/IAI.70.2.661-664.2002
Anthrax spores make an essential contribution to vaccine efficacy
Abstract
Anthrax is caused by Bacillus anthracis, a gram-positive spore-forming bacterium. Septicemia and toxemia rapidly lead to death in infected mammal hosts. Currently used acellular vaccines against anthrax consist of protective antigen (PA), one of the anthrax toxin components. However, in experimental animals such vaccines are less protective than live attenuated strains. Here we demonstrate that the addition of formaldehyde-inactivated spores (FIS) of B. anthracis to PA elicits total protection against challenge with virulent B. anthracis strains in mice and guinea pigs. The toxin-neutralizing activities of sera from mice immunized with PA alone or PA plus FIS were similar, suggesting that the protection conferred by PA plus FIS was not only a consequence of the humoral response to PA. A PA-deficient challenge strain was constructed, and its virulence was due solely to its multiplication. Immunization with FIS alone was sufficient to protect mice partially, and guinea pigs totally, against infection with this strain. This suggests that spore antigens contribute to protection. Guinea pigs and mice had very different susceptibilities to infection with the nontoxigenic strain, highlighting the importance of verifying the pertinence of animal models for evaluating anthrax vaccines.
Similar articles
-
Efficacy of a vaccine based on protective antigen and killed spores against experimental inhalational anthrax.Infect Immun. 2009 Mar;77(3):1197-207. doi: 10.1128/IAI.01217-08. Epub 2008 Dec 29. Infect Immun. 2009. PMID: 19114543 Free PMC article.
-
The role of antibodies to Bacillus anthracis and anthrax toxin components in inhibiting the early stages of infection by anthrax spores.Microbiology (Reading). 2001 Jun;147(Pt 6):1677-1685. doi: 10.1099/00221287-147-6-1677. Microbiology (Reading). 2001. PMID: 11390699
-
A novel live attenuated anthrax spore vaccine based on an acapsular Bacillus anthracis Sterne strain with mutations in the htrA, lef and cya genes.Vaccine. 2017 Oct 20;35(44):6030-6040. doi: 10.1016/j.vaccine.2017.03.033. Epub 2017 Mar 23. Vaccine. 2017. PMID: 28342664
-
Progress and novel strategies in vaccine development and treatment of anthrax.Immunol Rev. 2011 Jan;239(1):221-36. doi: 10.1111/j.1600-065X.2010.00969.x. Immunol Rev. 2011. PMID: 21198675 Review.
-
Recent progress in the development of anthrax vaccines.Recent Pat Biotechnol. 2011 Dec;5(3):148-59. doi: 10.2174/187220811797579097. Recent Pat Biotechnol. 2011. PMID: 22360464 Review.
Cited by
-
Inhalable vaccine of bacterial culture supernatant extract mediates protection against fatal pulmonary anthrax.Emerg Microbes Infect. 2023 Dec;12(1):2191741. doi: 10.1080/22221751.2023.2191741. Emerg Microbes Infect. 2023. PMID: 36920800 Free PMC article.
-
Capsules, toxins and AtxA as virulence factors of emerging Bacillus cereus biovar anthracis.PLoS Negl Trop Dis. 2015 Apr 1;9(4):e0003455. doi: 10.1371/journal.pntd.0003455. eCollection 2015 Apr. PLoS Negl Trop Dis. 2015. PMID: 25830379 Free PMC article.
-
Recombinant GroEL enhances protective antigen-mediated protection against Bacillus anthracis spore challenge.Med Microbiol Immunol. 2013 Apr;202(2):153-65. doi: 10.1007/s00430-012-0280-z. Epub 2012 Dec 21. Med Microbiol Immunol. 2013. PMID: 23263010
-
A Bivalent Protein r-PAbxpB Comprising PA Domain IV and Exosporium Protein BxpB Confers Protection Against B. anthracis Spores and Toxin.Front Immunol. 2019 Mar 19;10:498. doi: 10.3389/fimmu.2019.00498. eCollection 2019. Front Immunol. 2019. PMID: 30941133 Free PMC article.
-
Bacillus anthracis: balancing innocent research with dual-use potential.Int J Med Microbiol. 2008 Jul;298(5-6):345-64. doi: 10.1016/j.ijmm.2007.09.007. Epub 2008 Mar 28. Int J Med Microbiol. 2008. PMID: 18375178 Free PMC article. Review.
References
-
- Berthier, M., J. L. Fauchère, J. Perrin, B. Grignon, and D. Oriot. 1996. Fulminant meningitis due to Bacillus anthracis in 11-year-old girl during Ramadan. Lancet 347:828. - PubMed
-
- Cohen, S., I. Mendelson, Z. Altboum, D. Kobiler, E. Elhanany, T. Bino, M. Leitner, I. Inbar, H. Rosenberg, Y. Gozes, R. Barak, M. Fisher, C. Kronman, B. Velan, and A. Shafferman. 2000. Attenuated nontoxinogenic and nonencapsulated recombinant Bacillus anthracis spore vaccines protect against anthrax. Infect. Immun. 68:4549-4558. - PMC - PubMed
-
- Fellows, P. F., M. K. Linscott, B. E. Ivins, M. L. Pitt, C. A. Rossi, P. H. Gibbs, and A. M. Friedlander. 2001. Efficacy of a human anthrax vaccine in guinea pigs, rabbits, and rhesus macaques against challenge by Bacillus anthracis isolates of diverse geographical origin. Vaccine 19:3241-3247. - PubMed
-
- Friedlander, A. M., P. R. Pittman, and G. W. Parker. 1999. Anthrax vaccine: evidence for safety and efficacy against inhalational anthrax. JAMA 282:2104-2106. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical